Adcock Ingram eyes broad-based growth after striking product balance
Drug maker has been pushing into products that are not price regulated, which now contribute half of its revenue
25 August 2021 - 08:54
Local pharmaceutical manufacturer Adcock Ingram says its push into non-regulated products where it has better pricing power is paying off, but it is looking for growth across all its business divisions even as it grapples with pandemic-induced shifts in consumer spending.
The group, in which Bidvest has a controlling stake, has been bulking up its presence in areas such as shoe-care products, a move that has helped the revenue contribution from products that are not price regulated rise from about a third to just under half over the past two years...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.